GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (LSE:IMM) » Definitions » EBITDA Margin %

ImmuPharma (LSE:IMM) EBITDA Margin % : -1,538.57% (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is ImmuPharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ImmuPharma's EBITDA for the six months ended in Jun. 2023 was £-1.08 Mil. ImmuPharma's Revenue for the six months ended in Jun. 2023 was £0.07 Mil. Therefore, ImmuPharma's EBITDA margin for the quarter that ended in Jun. 2023 was -1,538.57%.


ImmuPharma EBITDA Margin % Historical Data

The historical data trend for ImmuPharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma EBITDA Margin % Chart

ImmuPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,650.62 -8,528.21 -5,388.98 -7,375.42 -

ImmuPharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12,079.17 -6,109.47 - - -1,538.57

Competitive Comparison of ImmuPharma's EBITDA Margin %

For the Biotechnology subindustry, ImmuPharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuPharma's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuPharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ImmuPharma's EBITDA Margin % falls into.



ImmuPharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ImmuPharma's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-4.337/0
= %

ImmuPharma's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-1.077/0.07
=-1,538.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmuPharma  (LSE:IMM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


ImmuPharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ImmuPharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuPharma (LSE:IMM) Business Description

Traded in Other Exchanges
Address
One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (LSE:IMM) Headlines

No Headlines